Bamlanivimab is authorized for patients with positive results of direct SARS-CoV-2 viral testing who are 12 years of age and older weighing at least 40 kilograms (about 88 pounds), and who are at high risk for progressing to severe COVID-19 and/or hospitalization. This includes those who are 18-55 years of age or older, or who have certain chronic medical conditions such as lung conditions, any complex medical conditions including autoimmune disorders. Including medical conditions that are not actively being treated by PCP. Bamlanivimab is authrozied for anyone who is older then 65 years of age and for patients over 40 years old who have BMI > greater than 35. Bamlanivimab is not authorized for patients who are hospitalized due to COVID-19 or require oxygen therapy due to COVID-19. A benefit of bamlanivimab treatment has not been shown in patients hospitalized due to COVID-19. Monoclonal antibodies, such as bamlanivimab, may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high flow oxygen or mechanical ventilation.